Need Help?

Single-cell TCR sequencing data from patients with nodal T follicular helper cell lymphomas enrolled in a phase 2 trial of dasatinib

This dataset contains single-cell TCR sequencing data from 22 peripheral blood (PB) samples collected from 11 patients with nodal T follicular helper cell lymphomas (TFHLs), generated using the Cell Ranger pipeline (v3.1.0, 10x Genomics) as part of a phase 2 trial of dasatinib.

Request Access

Policy for TFHL single-cell analysis project at Department of Hematology, University of Tsukuba

DATA ACCESS AGREEMENT These terms and conditions govern access to the managed access datasets (details of which are set out in Appendix I) to which the User Institution has requested access. The User Institution agrees to be bound by these terms and conditions. Definitions Authorised Personnel: The individuals at the User Institution to whom Department of Hematology, University of Tsukuba grants access to the Data. This includes the User, the individuals listed in Appendix II and any other individuals for whom the User Institution subsequently requests access to the Data. Details of the initial Authorised Personnel are set out in Appendix II. Data: The managed access datasets to which the User Institution has requested access. Data Producers: Department of Hematology, University of Tsukuba and the collaborators listed in Appendix I responsible for the development, organisation, and oversight of these Data. External Collaborator: A collaborator of the User, working for an institution other than the User Institution. Project: The project for which the User Institution has requested access to these Data. A description of the Project is set out in Appendix II. Publications: Includes, without limitation, articles published in print journals, electronic journals, reviews, books, posters and other written and verbal presentations of research. Research Participant: An individual whose data form part of these Data. Research Purposes: Shall mean research that is seeking to advance the understanding of genetics and genomics, including the treatment of disorders, and work on statistical methods that may be applied to such research. User: The principal investigator for the Project. User Institution(s): The Institution that has requested access to the Data. 1. The User Institution agrees to only use these Data for the purpose of the Project (described in Appendix II) and only for Research Purposes. The User Institution further agrees that it will only use these Data for Research Purposes which are within the limitations (if any) set out in Appendix I. 2. The User Institution agrees to preserve, at all times, the confidentiality of these Data. In particular, it undertakes not to use, or attempt to use these Data to compromise or otherwise infringe the confidentiality of information on Research Participants. Without prejudice to the generality of the foregoing, the User Institution agrees to use at least the measures set out in Appendix I to protect these Data. 3. The User Institution agrees to protect the confidentiality of Research Participants in any research papers or publications that they prepare by taking all reasonable care to limit the possibility of identification. 4. The User Institution agrees not to link or combine these Data to other information or archived data available in a way that could re-identify the Research Participants, even if access to that data has been formally granted to the User Institution or is freely available without restriction. 5. The User Institution agrees only to transfer or disclose these Data, in whole or part, or any material derived from these Data, to the Authorised Personnel. Should the User Institution wish to share these Data with an External Collaborator, the External Collaborator must complete a separate application for access to these Data. 6. The User Institution agrees that the Data Producers, and all other parties involved in the creation, funding or protection of these Data: a) make no warranty or representation, express or implied as to the accuracy, quality or comprehensiveness of these Data; b) exclude to the fullest extent permitted by law all liability for actions, claims, proceedings, demands, losses (including but not limited to loss of profit), costs, awards damages and payments made by the Recipient that may arise (whether directly or indirectly) in any way whatsoever from the Recipient’s use of these Data or from the unavailability of, or break in access to, these Data for whatever reason and; c) bear no responsibility for the further analysis or interpretation of these Data. 7. The User Institution agrees to follow the Fort Lauderdale Guidelines (http://www.wellcome.ac.uk/stellent/groups/corporatesite/@policy_communications/documents/web_document/wtd003207.pdf ) and the Toronto Statement (http://www.nature.com/nature/journal/v461/n7261/full/461168a.html). This includes but is not limited to recognising the contribution of the Data Producers and including a proper acknowledgement in all reports or publications resulting from the use of these Data. 8. The User Institution agrees to follow the Publication Policy in Appendix III. This includes respecting the moratorium period for the Data Producers to publish the first peer-reviewed report describing and analysing these Data. 9. The User Institution agrees not to make intellectual property claims on these Data and not to use intellectual property protection in ways that would prevent or block access to, or use of, any element of these Data, or conclusion drawn directly from these Data. 10. The User Institution can elect to perform further research that would add intellectual and resource capital to these data and decide to obtain intellectual property rights on these downstream discoveries. In this case, the User Institution agrees to implement licensing policies that will not obstruct further research and to follow the U.S. National Institutes of Health Best Practices for the Licensing of Genomic Inventions (2005) (https://www.icgc.org/files/daco/NIH_BestPracticesLicensingGenomicInventions_2005_en.pdf ) in conformity with the Organisation for Economic Co-operation and Development Guidelines for the Licensing of the Genetic Inventions (2006) (http://www.oecd.org/science/biotech/36198812.pdf ). 11. The User Institution agrees to destroy/discard the Data held, once it is no longer used for the Project, unless obliged to retain the data for archival purposes in conformity with audit or legal requirements. 12. The User Institution will notify Department of Hematology, University of Tsukuba within 30 days of any changes or departures of Authorised Personnel. 13. The User Institution will notify Department of Hematology, University of Tsukuba prior to any significant changes to the protocol for the Project. 14. The User Institution will notify Department of Hematology, University of Tsukuba as soon as it becomes aware of a breach of the terms or conditions of this agreement. 15. Department of Hematology, University of Tsukuba may terminate this agreement by written notice to the User Institution. If this agreement terminates for any reason, the User Institution will be required to destroy any Data held, including copies and backup copies. This clause does not prevent the User Institution from retaining these data for archival purpose in conformity with audit or legal requirements. 16. The User Institution accepts that it may be necessary for the Data Producers to alter the terms of this agreement from time to time. As an example, this may include specific provisions relating to the Data required by Data Producers other than Department of Hematology, University of Tsukuba. In the event that changes are required, the Data Producers or their appointed agent will contact the User Institution to inform it of the changes and the User Institution may elect to accept the changes or terminate the agreement. 17. If requested, the User Institution will allow data security and management documentation to be inspected to verify that it is complying with the terms of this agreement. 18. The User Institution agrees to distribute a copy of these terms to the Authorised Personnel. The User Institution will procure that the Authorised Personnel comply with the terms of this agreement. 19. This agreement (and any dispute, controversy, proceedings or claim of whatever nature arising out of this agreement or its formation) shall be construed, interpreted and governed by the laws of England and Wales and shall be subject to the exclusive jurisdiction of the English courts. Agreed for User Institution Signature: Name: Title: Date: Principal Investigator I confirm that I have read and understood this Agreement. Signature: Name: Title: Date: Agreed for Department of Hematology, University of Tsukuba Signature: Name: Sakurako Suma Title: Assistant professor, University of Tsukuba Hospital Date: APPENDIX I – DATASET DETAILS APPENDIX II ––PROJECT DETAILS APPENDIX III –– PUBLICATION POLICY APPENDIX I – DATASET DETAILS (to be completed by the data producer before passing to applicant) Dataset reference (EGA Study ID and Dataset Details) Tumor heterogeneity and immune-evasive microenvironment in T follicular helper cell lymphomas Mutation detection of T follicular helper cell lymphomas Name of project that created the dataset Tumor heterogeneity and immune-evasive microenvironment in T follicular helper cell lymphomas Names of other data producers/collaborators Mamiko Sakata-Yanagimoto Specific limitations on areas of research None Minimum protection measures required For each dataset that requires controlled access, there is a corresponding Data Access Committee (DAC) who determine access permissions. File access: Data can be held in unencrypted files on an institutional compute system, with Unix user group read/write access for one or more appropriate groups but not Unix world read/write access behind a secure firewall. Laptops holding these data should have password protected logins and screenlocks (set to lock after 5 min of inactivity). If held on USB keys or other portable hard drives, the data must be encrypted. APPENDIX II – PROJECT DETAILS (to be completed by the Requestor) Details of dataset requested i.e., EGA Study and Dataset Accession Number Brief abstract of the Project in which the Data will be used (500 words max) All Individuals who the User Institution to be named as registered users Name of Registered User Email Job Title Supervisor* All Individuals that should have an account created at the EGA Name of Registered User Email Job Title APPENDIX III – PUBLICATION POLICY In any publications based on these data, please cite Sakurako Suma et al, Leukemia 2024 and describe how the data can be accessed, including the name of the hosting database (e.g., The European Genome-phenome Archive at the European Bioinformatics Institute) and its accession numbers (e.g., EGAS00000000029), and acknowledge its use in a form agreed by the User Institution with Department of Hematology, University of Tsukuba.

Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.

Study ID Study Title Study Type
EGAS50000001240 Transcriptome Sequencing

This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.

ID File Type Size Quality Report
Located in
EGAF50000094968 csv 782.6 kB
EGAF50000094969 csv 79.2 kB
EGAF50000094970 csv 139.6 kB
EGAF50000094971 csv 526.8 kB
EGAF50000094972 csv 1.1 kB
EGAF50000095018 csv 1.7 MB
EGAF50000095019 csv 179.3 kB
EGAF50000095020 csv 329.0 kB
EGAF50000095021 csv 928.3 kB
EGAF50000095022 csv 1.1 kB
EGAF50000426581 csv 1.5 MB
EGAF50000426582 csv 108.8 kB
EGAF50000426583 csv 198.9 kB
EGAF50000426584 csv 525.4 kB
EGAF50000426585 csv 1.1 kB
EGAF50000426586 csv 1.1 kB
EGAF50000426587 csv 1.6 MB
EGAF50000426588 csv 78.9 kB
EGAF50000426589 csv 140.8 kB
EGAF50000426590 csv 1.0 MB
EGAF50000426591 csv 906.3 kB
EGAF50000426592 csv 1.2 MB
EGAF50000426593 csv 87.1 kB
EGAF50000426594 csv 155.6 kB
EGAF50000426595 csv 1.1 kB
EGAF50000426596 csv 1.2 MB
EGAF50000426597 csv 84.5 kB
EGAF50000426598 csv 150.5 kB
EGAF50000426599 csv 842.0 kB
EGAF50000426600 csv 1.1 kB
EGAF50000426614 csv 1.5 MB
EGAF50000426615 csv 48.3 kB
EGAF50000426616 csv 87.1 kB
EGAF50000426617 csv 386.5 kB
EGAF50000426618 csv 1.1 kB
EGAF50000426619 csv 777.0 kB
EGAF50000426620 csv 1.1 kB
EGAF50000426621 csv 1.2 MB
EGAF50000426622 csv 98.9 kB
EGAF50000426623 csv 177.2 kB
EGAF50000426624 csv 1.2 MB
EGAF50000426625 csv 132.1 kB
EGAF50000426626 csv 236.5 kB
EGAF50000426627 csv 906.5 kB
EGAF50000426628 csv 1.1 kB
EGAF50000426629 csv 1.8 MB
EGAF50000426630 csv 1.1 kB
EGAF50000426631 csv 152.3 kB
EGAF50000426632 csv 273.1 kB
EGAF50000426633 csv 1.2 MB
EGAF50000426634 csv 1.0 MB
EGAF50000426635 csv 1.1 kB
EGAF50000426636 csv 735.0 kB
EGAF50000426637 csv 140.1 kB
EGAF50000426638 csv 250.1 kB
EGAF50000426639 csv 1.3 MB
EGAF50000426640 csv 101.9 kB
EGAF50000426641 csv 180.9 kB
EGAF50000426642 csv 841.0 kB
EGAF50000426643 csv 1.1 kB
EGAF50000426644 csv 871.9 kB
EGAF50000426645 csv 54.1 kB
EGAF50000426646 csv 97.6 kB
EGAF50000426647 csv 382.0 kB
EGAF50000426648 csv 1.1 kB
EGAF50000426649 csv 476.5 kB
EGAF50000426650 csv 1.1 kB
EGAF50000426651 csv 912.0 kB
EGAF50000426652 csv 55.7 kB
EGAF50000426653 csv 101.5 kB
EGAF50000426654 csv 1.1 MB
EGAF50000426655 csv 1.5 MB
EGAF50000426656 csv 152.2 kB
EGAF50000426657 csv 276.1 kB
EGAF50000426658 csv 1.1 kB
EGAF50000426659 csv 695.7 kB
EGAF50000426660 csv 923.7 kB
EGAF50000426661 csv 122.5 kB
EGAF50000426662 csv 219.2 kB
EGAF50000426663 csv 1.1 kB
EGAF50000426664 csv 1.3 MB
EGAF50000426665 csv 121.6 kB
EGAF50000426666 csv 218.2 kB
EGAF50000426667 csv 882.6 kB
EGAF50000426668 csv 1.1 kB
EGAF50000426669 csv 149.8 kB
EGAF50000426670 csv 704.7 kB
EGAF50000426671 csv 1.1 kB
EGAF50000426672 csv 900.7 kB
EGAF50000426673 csv 84.0 kB
EGAF50000426674 csv 849.6 kB
EGAF50000426675 csv 1.1 kB
EGAF50000426676 csv 1.2 MB
EGAF50000426677 csv 179.3 kB
EGAF50000426678 csv 322.5 kB
EGAF50000426679 csv 1.4 MB
EGAF50000426680 csv 56.2 kB
EGAF50000426681 csv 100.2 kB
EGAF50000426682 csv 1.1 MB
EGAF50000426683 csv 1.1 kB
EGAF50000426696 csv 170.8 kB
EGAF50000426697 csv 309.3 kB
EGAF50000426698 csv 805.7 kB
EGAF50000426699 csv 1.3 MB
EGAF50000426700 csv 1.1 kB
EGAF50000426750 csv 398.4 kB
EGAF50000426751 csv 1.1 kB
EGAF50000426752 csv 1.2 MB
EGAF50000426753 csv 37.5 kB
EGAF50000426754 csv 67.0 kB
110 Files (51.2 MB)